Rice Hall James & Associates LLC Takes $22.80 Million Position in Supernus Pharmaceuticals, Inc. $SUPN

Posted by Francis Steltz on Aug 18th, 2026

Rice Hall James & Associates LLC acquired a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 490,221 shares of the specialty pharmaceutical company’s stock, valued at approximately $22,800,000. Supernus Pharmaceuticals makes up about 1.1% of Rice Hall James & Associates LLC’s portfolio, making the stock its 28th largest holding. Rice Hall James & Associates LLC owned approximately 0.84% of Supernus Pharmaceuticals at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in SUPN. Rockefeller Capital Management L.P. lifted its position in Supernus Pharmaceuticals by 354.8% in the 4th quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock valued at $42,000 after acquiring an additional 660 shares in the last quarter. Torren Management LLC bought a new position in Supernus Pharmaceuticals during the 4th quarter worth about $49,000. EverSource Wealth Advisors LLC bought a new position in Supernus Pharmaceuticals during the 2nd quarter worth about $51,000. Hantz Financial Services Inc. raised its stake in shares of Supernus Pharmaceuticals by 73.3% in the 4th quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company’s stock valued at $54,000 after purchasing an additional 458 shares during the period. Finally, Raymond James Financial Inc. acquired a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter valued at about $55,000.

Analyst Upgrades and Downgrades

SUPN has been the subject of several recent research reports. Wall Street Zen cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Cantor Fitzgerald lifted their target price on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a research report on Thursday, July 9th. Zacks Research upgraded Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 6th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, June 24th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Supernus Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $62.83.

Check Out Our Latest Stock Report on Supernus Pharmaceuticals

Supernus Pharmaceuticals Stock Performance

Shares of SUPN opened at $48.27 on Tuesday. The company has a market cap of $2.81 billion, a price-to-earnings ratio of -25.14, a PEG ratio of 0.89 and a beta of 0.56. Supernus Pharmaceuticals, Inc. has a 1-year low of $41.78 and a 1-year high of $59.68. The company’s fifty day simple moving average is $46.54 and its 200 day simple moving average is $48.85.

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) last announced its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of $0.42 by ($1.43). The firm had revenue of $219.06 million during the quarter, compared to analyst estimates of $205.31 million. Supernus Pharmaceuticals had a negative net margin of 13.23% and a positive return on equity of 11.13%. The business’s revenue was up 32.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.40 EPS. As a group, research analysts forecast that Supernus Pharmaceuticals, Inc. will post 1.97 earnings per share for the current year.

Supernus Pharmaceuticals Company Profile

(Free Report)

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.